• In the past week, Intuitive Surgical reported fiscal Q2 2026 results that exceeded revenue and adjusted EPS forecasts, while also updating its bylaws to align shareholder voting and nomination rules with recent SEC universal proxy requirements.
• Despite solid global procedure expansion across da Vinci and Ion systems, investors focused on moderating U.S. procedure growth and tighter governance procedures that could shape future shareholder influence and board elections.
• We’ll now examine how strong results but slowing U.S. procedure growth reshape Intuitive Surgical’s investment narrative built around utilization and innovation.

We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Intuitive Surgical Investment Narrative Recap

To own Intuitive Surgical, you have to believe robotic-assisted surgery will keep gaining share globally, supporting recurring instrument and service revenue tied to a growing installed base. The key near term catalyst remains procedure growth and utilization, especially in the U.S., while the biggest risk is any sustained slowdown in procedure volumes or hospital spending. The latest Q2 beat and stock selloff largely sharpen, rather than fundamentally change, that focus on utilization and pricing power.

The recent bylaw revisions around proxy rules and director nominations matter mainly for governance sensitive investors, but they do not materially change the near term business outlook compared with the Q2 results. In contrast, Q2’s 16% worldwide procedure growth, alongside concerns about moderating U.S. trends, feeds directly into the central catalyst of system utilization and the risk that hospitals trim or delay future robotic surgery investments.

Yet beneath the strong global growth story, investors should be aware of how moderating U.S. procedure trends and rising competitive pressures could...

Intuitive Surgical's narrative projects $15.6 billion revenue and $4.7 billion earnings by 2029.

Uncover how Intuitive Surgical's forecasts yield a $501.73 fair value, a 25% upside to its current price.

Exploring Other Perspectives

Before this Q2 surprise, the most optimistic analysts were banking on around US$16.7 billion of revenue and US$4.9 billion of earnings by 2029, a far more aggressive view than consensus that could be tested if slower U.S. procedures or tighter hospital budgets start to bite.

Explore 11 other fair value estimates on Intuitive Surgical - why the stock might be worth as much as 57% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Intuitive Surgical research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Intuitive Surgical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Intuitive Surgical's overall financial health at a glance.

Contemplating Other Strategies?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.